Acceleron Pharma Inc. is a biopharmaceutical firm dedicated to discovering, advancing, and bringing to market treatments for severe and uncommon illnesses. Its flagship product, REBLOZYL (luspatercept-aamt), addresses anemia in adult patients afflicted with beta-thalassemia. The company's pipeline includes additional applications for luspatercept-aamt targeting myelodysplastic syndromes and myelofibrosis. Furthermore, it is developing Sotatercept for patients suffering from pulmonary arterial hypertension. A neuromuscular therapeutic candidate, ACE-083, is currently undergoing Phase II clinical trials to treat Charcot-Marie-Tooth disease. Acceleron has also forged strategic alliances, including a collaboration, license, and option pact with Celgene Corporation. Another partnership with Fulcrum Therapeutics, Inc. focuses on a collaboration and license agreement to pinpoint small molecules capable of modulating particular pathways relevant to specific pulmonary conditions. Initially established in 2003 as Phoenix Pharma, Inc., the company, now known as Acceleron Pharma Inc., maintains its headquarters in Cambridge, Massachusetts.